Novel targets and therapies for keloid

• Published in: Clinical and experimental dermatology Vol. 47; no. 3; pp. 507 - 515
• Main Author: Naik, P. P.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.03.2022
• Subjects: Angiotensin; Bleomycin; Botulinum toxin type A; Cell therapy; Collagen (type III); Corticosteroids; Cryotherapy; Epigenetics; Esthetics; Gene therapy; Humans; Interferon; Keloid - etiology; Keloid - pathology; Keloid - psychology; Keloid - therapy; Laser radiation; Mitomycin C; Quality of Life; Radiofrequency ablation; Reconstructive surgery; Recurrence; Stem cells; Stress, Psychological - etiology
• ISSN: 0307-6938; 1365-2230; 1365-2230
• DOI: 10.1111/ced.14920

Summary Keloids are the result of aberrant tissue scarring typically occurring in injured skin, and are caused by the overgrowth of granulation tissue or collagen type III during the healing process. There is a genetic component, thus a predisposition can be genetically transmitted. Keloids are difficult to treat because of their postexcisional recurrence, and they have an impact on patient quality of life due to psychological distress caused by cosmetic concerns and functional disability. Treatment ranges from classic corticosteroid therapy to multimodal approaches such as injections, cryotherapy, laser, radiation, radiofrequency ablation and extracorporeal shockwave therapy. Recent discoveries into the pathogenesis of keloid have enabled clinicians to expand the therapeutic options for treatment. The aim of this paper was to review the literature, clarify the general concept of keloid development, and assess emerging treatment options such as stem cell therapy, mitomycin C, bleomycin, interferon, botulinum toxin type A, calcium channel blockers, angiotensin‐converting enzyme inhibitors and fat grafting, and the evolutionary advancement towards epigenetic modifications and gene therapy.